In CRC, NTRK fusions are identified in approximately 0.2–0.3% of unselected cases, with enrichment in MSI, RAS/BRAF wild-type tumors, particularly those with a sessile serrated pathway origin. This evidence concerns the gene BRAF and colorectal carcinoma.